Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.
Daniel A
DA
Hussar
Angelique
A
Nguyen
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006020:Glycopeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D000077427:Lipoglycopeptides; D010755:Organophosphates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010080:Oxazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017334:Teicoplanin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014640:Vancomycin / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D010755:Organophosphates; D010080:Oxazoles; D017334:Teicoplanin; C469289:dalbavancin; C543529:vedolizumab; C515040:tedizolid phosphate; C100708:oritavancin; D014640:Vancomycin